Targeted Methylation of the Epithelial Cell Adhesion Molecule (EpCAM) Promoter to Silence Its Expression in Ovarian Cancer Cells
暂无分享,去创建一个
Albert Jeltsch | Richard Reinhardt | R. Reinhardt | A. Jeltsch | S. Ragozin | Suneetha Nunna | Sergey Ragozin | Suneetha Nunna
[1] Albert Jeltsch,et al. Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. , 2013, Journal of molecular biology.
[2] T. Bestor,et al. Cytosine methylation targetted to pre-determined sequences , 1997, Nature Genetics.
[3] M. Rots,et al. EpCAM in carcinogenesis: the good, the bad or the ugly. , 2010, Carcinogenesis.
[4] M. Rots,et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer , 2012, Nucleic acids research.
[5] Brigitte Mack,et al. Nuclear signalling by tumour-associated antigen EpCAM , 2009, Nature Cell Biology.
[6] I. Nagtegaal,et al. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. , 2003, The American journal of pathology.
[7] K. Tai,et al. DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression , 2007, Oncogene.
[8] H. Moch,et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. , 2006, Gynecologic oncology.
[9] L. Galluzzi,et al. Molecular mechanisms of cisplatin resistance , 2012, Oncogene.
[10] Pernette J. Verschure,et al. Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes , 2012, Nucleic acids research.
[11] Peter A. Jones. Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.
[12] James E. Frampton. Catumaxomab: in malignant ascites. , 2012, Drugs.
[13] A. Jeltsch,et al. Structure and Function of Mammalian DNA Methyltransferases , 2011, Chembiochem : a European journal of chemical biology.
[14] Y. Hannun,et al. EpCAM Is Overexpressed in Breast Cancer and Is a Potential Target for Breast Cancer Gene Therapy , 2004, Cancer Research.
[15] M. Rots,et al. Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer , 2013, British Journal of Cancer.
[16] Tom H. Pringle,et al. The human genome browser at UCSC. , 2002, Genome research.
[17] Howard Cedar,et al. Programming of DNA methylation patterns. , 2012, Annual review of biochemistry.
[18] W. Parson,et al. Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. , 2007, Cancer letters.
[19] Aaron Klug,et al. In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence , 1994, Nature.
[20] C. Barbas,et al. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.
[21] M. Rots,et al. Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein‐2 promoter as a novel anti‐cancer treatment , 2007, Molecular carcinogenesis.
[22] T. Raum,et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. , 2006, European journal of cancer.
[23] H. A. Bakker,et al. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule , 1994, The Journal of cell biology.
[24] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[25] S. Cannistra. Cancer of the ovary. , 1993, The New England journal of medicine.
[26] A Klug,et al. Toward a code for the interactions of zinc fingers with DNA: selection of randomized fingers displayed on phage. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[27] C. Barbas,et al. Building zinc fingers by selection: toward a therapeutic application. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[28] Pilar Blancafort,et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation , 2012, Epigenetics.
[29] R. Reinhardt,et al. DNA methylation analysis by bisulfite conversion, cloning, and sequencing of individual clones. , 2009, Methods in molecular biology.
[30] Tim Hui-Ming Huang,et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] J. Barnholtz-Sloan,et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. , 2003, American journal of obstetrics and gynecology.
[32] D J Segal,et al. Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[33] Alessandro Lugli,et al. Frequent EpCam protein expression in human carcinomas. , 2004, Human pathology.
[34] W. Duan,et al. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule , 2011, Cancer science.
[35] J. Thiery. The saga of adhesion molecules , 1996, Journal of cellular biochemistry.
[36] R. Kimmig,et al. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. , 2009, Anticancer research.
[37] Lalit Kumar,et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.
[38] D. Seimetz,et al. Catumaxomab: clinical development and future directions. , 2010, mAbs.
[39] Margaret Gardiner-Garden,et al. Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer , 2004, Clinical Cancer Research.
[40] Albert Jeltsch,et al. BISMA - Fast and accurate bisulfite sequencing data analysis of individual clones from unique and repetitive sequences , 2010, BMC Bioinformatics.
[41] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[42] Erin L. Doyle,et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting , 2011, Nucleic acids research.
[43] Stefan Sleijfer,et al. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. , 2009, Cancer treatment reviews.
[44] M. Rots,et al. Persistent downregulation of the pancarcinoma‐associated epithelial cell adhesion molecule via active intranuclear methylation , 2008, International journal of cancer.
[45] M. Rots,et al. Targeted DNA Methylation by a DNA Methyltransferase Coupled to a Triple Helix Forming Oligonucleotide To Down-Regulate the Epithelial Cell Adhesion Molecule , 2010, Bioconjugate chemistry.
[46] C. Bokemeyer. Catumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites , 2010, Expert opinion on biological therapy.
[47] L. Schwartzberg. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. , 2001, Critical reviews in oncology/hematology.
[48] A. Jeltsch,et al. Silencing of gene expression by targeted DNA methylation: concepts and approaches. , 2010, Methods in molecular biology.
[49] S H Kim,et al. In vitro selection of zinc fingers with altered DNA-binding specificity. , 1994, Biochemistry.
[50] M. Pensabene,et al. New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches , 2013, BioMed research international.
[51] A. Bird,et al. DNA methylation landscapes: provocative insights from epigenomics , 2008, Nature Reviews Genetics.
[52] C. Bokemeyer,et al. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. , 2010, Cancer treatment reviews.
[53] A. Bogdanove,et al. TAL Effectors: Customizable Proteins for DNA Targeting , 2011, Science.
[54] M. Rots,et al. Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer , 2011, British Journal of Cancer.
[55] S. Leung,et al. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.
[56] A. Plückthun,et al. Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy , 2013, Expert opinion on drug delivery.
[57] Markus Münz,et al. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation , 2004, Oncogene.
[58] Albert Jeltsch,et al. Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes , 2006, Nucleic acids research.
[59] C. Pabo,et al. Zinc finger phage: affinity selection of fingers with new DNA-binding specificities. , 1994, Science.
[60] R. Kimmig,et al. Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells , 2003, Journal of Cancer Research and Clinical Oncology.
[61] A. Jeltsch,et al. Application of DNA methyltransferases in targeted DNA methylation , 2007, Applied Microbiology and Biotechnology.
[62] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[63] J. Berek,et al. Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.
[64] Julie A. Law,et al. Establishing, maintaining and modifying DNA methylation patterns in plants and animals , 2010, Nature Reviews Genetics.
[65] G. Schäfer,et al. Overexpression of Epithelial Cell Adhesion Molecule Antigen in Gallbladder Carcinoma Is an Independent Marker for Poor Survival , 2004, Clinical Cancer Research.
[66] O. Gires,et al. EpCAM (CD326) finding its role in cancer , 2007, British Journal of Cancer.
[67] P. Went,et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis , 2011, Journal of Clinical Pathology.